BioSpace News Archive

Partners STADA and Alvotech announced that the European Commission issued a marketing authorization for Uzpruvo®, a biosimilar candidate to Stelara®.

Valneva SE announced that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s single-shot chikungunya vaccine.

The Centre for Chinese Herbal Medicine Drug Development of Hong Kong Baptist University (HKBU) has developed a new drug using effective components of a Chinese herbal medicine, Chaenomelis Fructus, for the treatment of the rare disease, myofibrillar myopathy.

Nanoflex Robotics AG, a remote robotic surgical company based in Switzerland, has received the internationally recognized ISO 13485 certification for its quality management system in designing and manufacturing remote robotic devices for endovascular interventions.

Guangzhou Fermion Technology Co., Ltd. has announced today that China National Medical Products Administration (NMPA) approved the Investigational New Drug (IND) application for its non-addictive pain relief drug FZ008-145.

Bio-Path Holdings, Inc., today announced completion of the first dose cohort of the dose escalation portion of its Phase 1 clinical trial of BP1002 evaluating the ability of BP1002, a liposomal Bcl-2 nanoparticle antisense, for the treatment of refractory/relapsed lymphoma and refractory/relapsed chronic lymphocytic leukemia (CLL) patients.

Alkeus Pharmaceuticals, Inc., today announced positive interim data showing gildeuretinol halted Stargardt disease progression for up to six years.

Amarin Corporation plc (NASDAQ:AMRN) today provided a business update, including preliminary unaudited fourth quarter 2023 revenue and its year-end cash position, its 2023 progress and 2024 priorities and its plan to initiate a share repurchase program, ahead of its presentation to investors at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Revive Therapeutics Ltd. is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo.

EyePoint Pharmaceuticals, Inc. today announced that the first patient has been dosed in the Phase 2 VERONA clinical trial of EYP-1901 for diabetic macular edema (DME).